文献速递鼻科

奥马珠单抗治疗过敏性鼻炎:系统综述与荟萃分析

Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis.
PubMed 文献 · Rhinology · 2021-01-01

该系统综述与荟萃分析纳入12项随机对照试验,评估奥马珠单抗对控制不佳的过敏性鼻炎患者的疗效与安全性。结果显示奥马珠单抗可降低鼻部和眼部症状评分、改善生活质量、减少急救抗组胺药用量,且不良事件发生率与安慰剂无显著差异。

要点

  • 奥马珠单抗可降低过敏性鼻炎患者的每日鼻部症状严重程度评分。
  • 奥马珠单抗改善眼部症状评分及鼻结膜炎生活质量问卷评分。
  • 不良事件发生率与安慰剂相比无统计学显著差异。

核心结论

  • 研究结果进一步支持奥马珠单抗在常规治疗控制不佳的过敏性鼻炎患者中的疗效与安全性。

研究设计与样本

  • 系统文献检索评估奥马珠单抗治疗过敏性鼻炎安全性和有效性的随机对照试验,最终纳入12项随机对照试验进行数据提取和荟萃分析。

主要发现

  • 奥马珠单抗使每日鼻部症状严重程度评分的汇总标准化均数差降低-0.41分,异质性大。
  • 在3项雪松花粉诱导的过敏性鼻炎试验中,奥马珠单抗使每日鼻部症状严重程度评分降低-0.97分;在其余5项非雪松试验中降低-0.19分。
  • 奥马珠单抗使每日眼部症状严重程度评分的汇总标准化均数差降低-0.30分,异质性大。
  • 奥马珠单抗使鼻结膜炎生活质量问卷评分的汇总标准化均数差降低-0.45分,无异质性。
  • 奥马珠单抗使每日急救抗组胺药平均消耗量的汇总标准化均数差降低-0.21,异质性大;不良事件发生率与安慰剂相比无统计学显著差异。

临床怎么用

  • 对于常规治疗控制不佳的过敏性鼻炎患者,可考虑使用奥马珠单抗以改善症状和生活质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Allergic rhinitis (AR), an IgE mediated inflammatory disease, significantly impacts quality of life of a considerable proportion of the general population. Omalizumab, a humanized monoclonal antibody against IgE, has been evaluated for both seasonal and perennial AR. We aimed to assess the efficacy and safety of omalizumab in randomized controlled trials (RCTs) in inadequately controlled AR. METHODS: We conducted a systematic literature search of RCTs evaluating the safety and efficacy of omalizumab in AR. We synthesized evidence for clinical improvement of AR symptoms, quality of life, reduction of the use of rescue medication, and adverse events. RESULTS: The systematic search returned 289 articles, of which 12 RCTs were eligible for data extraction and meta-analysis. Omalizumab reduced the Daily Nasal Symptom Severity Score (DNSSS) by a summary standardized mean difference of -0.41 points with large heterogeneity; omalizumab significantly reduced the DNSSS both in the 3 cedar pollen-induced AR trials by -0.97 points and to a lower extent in the remaining five non-cedar trials by -0.19 points. Omalizumab also improved the Daily Ocular Symptom Severity Score (DOSSS) by a summary standardized mean difference of -0.30 points with large heterogeneity; the Rhino-conjunctivitis Quality of Life Questionnaire by a summary standardized mean difference of -0.45 points with no heterogeneity and the mean daily consumption of rescue antihistamines by a summary standardized mean difference of -0.21 with large heterogeneity. No statistically significant difference in the occurrence of adverse events was observed between omalizumab and placebo. CONCLUSION: Our findings further support the efficacy and safety of omalizumab in the management of patients with allergic rhinitis inadequately controlled with a conventional treatment.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Tsabouri S, Ntritsos G, Koskeridis F, et al. Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis. Rhinology. 2021. PMID: 34714895. doi:10.4193/Rhin21.159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。